FIELD: medicine. SUBSTANCE: method involves administering fluoruracyl daily at a dose of 0.1-2.5 mg/kg during at least 2 months in addition to isoniazide treatment. Isoniazide and fluoruracyl are administered concurrently and sequentially or as mixture or intravenously. EFFECT: enhanced effectiveness of treatment; eliminated changes of visceral organs; minimum isoniazide doses. 5 cl, 3 dwg, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTI-TUBERCULOSIS PREPARATION | 2002 |
|
RU2211035C1 |
METHOD FOR TREATING THE CASES OF EXPERIMENTAL TUBERCULOSIS | 2000 |
|
RU2165761C1 |
METHOD OF TREATMENT OF EXPERIMENTAL TUBERCULOSIS | 2001 |
|
RU2207127C1 |
METHOD FOR TREATING TUBERCULOSIS | 2004 |
|
RU2269346C1 |
DRUG PREPARATION FOR TREATING TUBERCULOSIS | 2013 |
|
RU2523792C9 |
TUBERCULOSTATIC AGENT | 2002 |
|
RU2207126C1 |
METHOD OF REDUCING INTOLERANCE TO ANTITUBERCULOUS PREPARATIONS | 2009 |
|
RU2412701C2 |
METHOD FOR TREATING PULMONARY TUBERCULOSIS AT PREDOMINANTLY PRODUCTIVE TYPE OF TISSUE REACTION | 2000 |
|
RU2204409C2 |
TUBERCULOSTAT AGENT | 2001 |
|
RU2185170C1 |
METHOD OF TREATING INFILTRATIVE PULMONARY TUBERCULOSIS INDUCED BY MULTIPLE-DRUG-RESISTANT AND HIGHLY TOXIC STRAINS OF MYCOBACTERIA TUBERCULOSIS | 2009 |
|
RU2423129C1 |
Authors
Dates
2003-09-20—Published
2002-03-18—Filed